Abstract
Objectives A polygenic hazard score (PHS1)—weighted sum of 54 single-nucleotide polymorphism genotypes—was previously associated with age at prostate cancer (PCa) diagnosis and improved PCa screening accuracy in Europeans. Performance in more diverse populations is unknown. We evaluated PHS association with PCa in multi-ethnic populations.
Design PHS1 was adapted for compatibility with genotype data from the OncoArray project (PHS2) and tested for association with age at PCa diagnosis, at aggressive PCa diagnosis, and at PCa death.
Setting Multiple international institutions.
Participants Men with available OncoArray data from the PRACTICAL consortium who were not included in PHS1 development/validation.
Main Outcomes and Measures PHS2 was tested via Cox proportional hazards models for age at PCa diagnosis, age at aggressive PCa diagnosis (any of: Gleason score ≥7, stage T3-T4, PSA≥10 ng/mL, nodal/distant metastasis), and age at PCa-specific death.
Results 80,491 men of various self-reported race/ethnicities were included (30,575 controls, 49,916 PCa cases; genetic ancestry groups: 71,856 European, 6,253 African, 2,382 Asian). Median age at last follow-up was 70 years (IQR 63-76); 3,983 PCa deaths, 5,806 other deaths, 70,702 still alive. PHS2 had 46 polymorphisms: 24 directly genotyped and 22 acceptable proxies (r2 ≥0.94). PHS2 was associated with age at PCa diagnosis in the multi-ethnic dataset (z=54, p<10-16) and in each genetic ancestry group: European (z=56, p<10-16), Asian (z=47, p<10-16), African (z=29, p<10-16). PHS2 was also associated with age at aggressive PCa diagnosis in each genetic ancestry group (p<10-16) and with age of PCa death in the full dataset (p<10-16). Comparing the 80th and 20th percentiles of genetic risk, men with high PHS had hazard ratios of 5.3 [95% CI: 5.0-5.7], 5.9 [5.5-6.3], and 5.7 [4.6-7.0] for PCa, aggressive PCa, and PCa-specific death, respectively. Within European, Asian, and African ancestries, analogous hazard ratios for PCa were 5.5 [5.2-5.9], 4.5 [3.2-6.3], and 2.5 [2.1-3.1], respectively.
Conclusions PHS2 is strongly associated with age at PCa diagnosis in a multi-ethnic dataset. PHS2 stratifies men of European, Asian, and African ancestry by genetic risk for any, aggressive, and fatal PCa.
What is already known on this topic
Genetic risk stratification can identify men with greater predisposition for developing prostate cancer, but these risk models may worsen health disparities, as most have only been validated for men of European ancestry
A polygenic hazard score was previously associated with age at prostate cancer diagnosis and improved PCa screening accuracy in Europeans
Performance of the polygenic hazard score in multi-ethnic populations is unknown
What this study adds
In a dataset from 80,491 men of various self-reported race/ethnicities, the polygenic hazard score was associated with age at prostate cancer diagnosis, aggressive prostate cancer diagnosis, and prostate cancer death.
PHS stratifies men of European, Asian, and African ancestry by genetic risk for any, aggressive, and fatal prostate cancer.
Competing Interest Statement
All authors declare no support from any organization for the submitted work except as follows: AM Dale and TM Seibert report a research grant from the US Department of Defense. OA Andreassen reports research grants from KG Jebsen Stiftelsen, Research Council of Norway, and South East Norway Health Authority. N Usmani reports grants from Astra Zeneca and Astellas, research collaboration and financial in kind support from Best Medical Canada and Concure Oncology. RM Martin reports grants from Cancer Research UK, during the conduct of the study. KD Sørensen reports grants from Danish Cancer Society, grants from Velux Foundation, during the conduct of the study. Authors declare no financial relationships with any organizations that might have an interest in the submitted work in the previous three years except as follows, with all of these relationships outside the present study: TM Seibert reports honoraria from Multimodal Imaging Services Corporation for imaging segmentation, honoraria from WebMD, Inc. for educational content, as well as a past research grant from Varian Medical Systems. AS Kibel reports advisory board memberships for Sanofi-Aventis, Dendreon, and Profound. RA Eeles reports honoraria from GU-ASCO, honoraria/speaker fees from Janssen, honoraria from an invited talk to the University of Chicago, and educational honoraria from Bayer&Ipsen. KD Sørensen reports personal fees from AstraZeneca, personal fees from Sanofi, outside the submitted work. N Usmani reports honoraria from Janssen Canada and Bayer, outside the submitted work. M Gamulin reports speaker/advisor board/travel fees for: BMS, Pfizer, Novartis, Astellas, Sanofi, Janssen, Roche, Sandoz, Amgen, Bayer, PharmaSwiss, MSD, Alvogen. M Gamuli also reports non-financial report for drugs from BMS, Roche, Janssen. Authors declare no other relationships or activities that could appear to have influenced the submitted work except as follows: OA Andreassen has a patent application # U.S. 20150356243 pending; AM Dale also applied for this patent application and assigned it to UC San Diego. AM Dale has additional disclosures outside the present work: founder, equity holder, and advisory board member for CorTechs Labs, Inc.; advisory board member of Human Longevity, Inc.; recipient of nonfinancial research support from General Electric Healthcare. KD Sørensen has a patent (Biomarkers for prostate cancer) issued to Qiagen, a patent (A microRNA-based method for early detection of prostate cancer in urine samples) issued to Qiagen, and a patent (A microRNA-based method for assessing the prognosis of a prostate cancer patient), issued to Qiagen. N Usmani has a patent Theranostic radiophotodynamic therapy nanoparticles pending, and a patent Hand-held device and computer implemented system and method for assisted steering of a percutaneously inserted needle pending. Additional acknowledgments for the PRACTICAL consortium and contributing studies are described in the Supplemental Material.
Funding Statement
This study was funded in part by a grant from the United States National Institute of Health/National Institute of Biomedical Imaging and Bioengineering (#K08EB026503), United States Department of Defense (#W81XWH-13-1-0391), the Research Council of Norway (#223273), KG Jebsen Stiftelsen, and South East Norway Health Authority. RMM is supported in part by the National Institute for Health Research Bristol Biomedical Research Centre. The CAP trial is funded by Cancer Research UK and the UK Department of Health (C11043/A4286, C18281/A8145, C18281/A11326, C18281/A15064, and C18281/A24432). RMM was supported by a Cancer Research UK (C18281/A19169) programme grant (the Integrative Cancer Epidemiology Programme). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the UK National Institute for Health Research (NIHR) or the Department of Health and Social Care.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Additional members from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome consortium (PRACTICAL, http://practical.icr.ac.uk/) are provided in the Supplemental Material.
Data Availability
The data used in this work were obtained from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium, and from the ProtecT study. PRACTICAL consists of a collaborative group of researchers, each of whom retains ownership of their contributed data. Members of the consortium can use pooled data via proposals that are reviewed by the Data Access Committee. Approved proposals are then sent to the principal investigators of the PRACTICAL member studies, each of whom may opt to participate or not in the specific request. Readers interested in participating in the PRACTICAL consortium and gaining access to member data may find information about application at: http://practical.icr.ac.uk. ProtecT (http://www.bristol.ac.uk/population-health-sciences/projects/protect/) study data were provided by the principal investigators for the trials who retain ownership of this data; access to these data can be requested by contacting those principal investigators and submitting a request form for approval.
